Get the Stockscreener App
83.41
0.20%
-0.17
After Hours:
83.41
Spyre Therapeutics Inc stock is traded at $83.41, with a volume of 1.34M.
It is down -0.20% in the last 24 hours and up +11.33% over the past month.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$83.58
Open:
$83.54
24h Volume:
1.34M
Relative Volume:
1.18
Market Cap:
$7.24B
Revenue:
$688.00K
Net Income/Loss:
$-168.74M
P/E Ratio:
-35.38
EPS:
-2.3577
Net Cash Flow:
$-185.87M
1W Performance:
+9.12%
1M Performance:
+11.33%
6M Performance:
+152.99%
1Y Performance:
+385.51%
1-Day Range:
$81.70
$84.92
1-Week Range:
$74.79
$84.92
52-Week Range:
$13.93
$84.92
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
83.41 | 7.26B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112 - Moomoo
Spyre Therapeutics (SYRE) Reveals Promising Results from SKYLINE Trial - GuruFocus
Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating - marketscreener.com
Spyre reports positive phase 2 trial results for UC drug By Investing.com - Investing.com South Africa
Spyre reports positive phase 2 trial results for UC drug - Investing.com UK
Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - The Manila Times
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p - TradingView
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Certain Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
SYRE completes enrollment in SKYWAY basket study on SPY072, stock up - MSN
Spyre Therapeutics stock hits 52-week high at 79.75 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 79.75 USD - Investing.com
Capital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Spyre Therapeutics grants inducement awards to four employees - scanx.trade
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Part of Equity Inducement Awards - Quiver Quantitative
Arrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE Maintains Buy Rating by Deutsche Bank -- Price Target Raised to $115 - GuruFocus
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - sharewise.com
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Deutsche Bank raises Spyre stock price target on competitor setback By Investing.com - Investing.com South Africa
Deutsche Bank raises Spyre stock price target on competitor setback - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock By Investing.com - Investing.com South Africa
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock - Investing.com UK
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock - Investing.com
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyre Therapeutics Inc Stock (SYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sloan Sheldon | Chief Medical Officer |
Jun 03 '26 |
Sale |
75.00 |
8,333 |
624,975 |
0 |
| Turtle Cameron | Chief Executive Officer |
Jun 01 '26 |
Sale |
70.43 |
15,000 |
1,056,486 |
597,540 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
105,494 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Sale |
71.06 |
7,500 |
532,937 |
97,994 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):